Kernal Biologics to Present at the 3rd Annual mRNA Process Development & Manufacturing Summit
CAMBRIDGE, Mass., September 18, 2024/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing immunotherapies designed to improve patients' survival rate and quality of life — today announced it is presenting in person at the mRNA Process Development & Manufacturing Summit in Boston, MA. The presentation highlights novel solutions to process development challenges resulting from the scale-up of DOE-optimized IVT reactions for KR-335, an immunotherapeutic mRNA-LNP that Kernal Bio has rationally designed using its mRNA 2.0 platform to be selectively translated into therapeutic proteins within the tumor microenvironment. These novel development and manufacturing solutions enable Kernal Bio to accelerate development and clinical manufacturing while maintaining stringent quality control criteria.
“Developing scalable and robust processes for mRNA-LNP therapeutics is critical to ensuring the safety and efficacy observed in preclinical models is rapidly and reliably advanced into the clinic,” said Kernal Bio’s Vice President of CMC, Joe Parrella. “At the mRNA Process Development & Manufacturing Summit, we look forward to highlighting the downstream purification challenges resulting from scaling up DOE-optimized IVT reactions and reviewing novel solutions that simplify manufacturing while maximizing yield and product quality.
Details for the Kernal Bio presentation are as follows:
Presentation Title: Addressing purification challenges resulting from scale-up of DOE-optimized IVT reactions
Conference: mRNA Process Development and Manufacturing Summit
Presenter: Joseph Parrella
Time: September 18, 2004; 11:00 am
Place: Boston, MA
About Kernal Biologics, Inc.
Kernal Bio is pioneering the engineering of human cells inside the body using selective mRNA-LNP technology to fight cancer and autoimmune diseases. By delivering antibody-decorated lipid nanoparticles (LNPs) that precisely target specific cell types, AI-designed mRNAs ensure high specificity and minimize off-target effects within the body. Kernal Bio has demonstrated remarkably high in vivo delivery efficiency (>90%) with our T-cell-targeted mRNA LNPs. Recently, by deploying these for in situ CAR T programming, the company achieved successfully in vivo B-cell depletion within a week. KR-402 program is being developed for hematological malignancies and autoimmune disorders. The cancer cell-targeting program, KR-335, boasts a 100x therapeutic index, showing high efficacy in solid tumors resistant to conventional immuno-oncology agents. It demonstrated strong tolerability in preclinical models, including mice and non-human primates.
With roots in MIT, Harvard, Merck, and BMS, the management team has led the way with three FDA-approved therapies and 120+ patents. Based in Cambridge, MA, and backed by investors like Hummingbird Ventures, Amgen Ventures, and NASA, Kernal Bio is revolutionizing mRNA therapeutics by harnessing AI to direct precision treatments within the body.
About the mRNA2.0 Platform
Kernal Bio is at the forefront of mRNA therapeutics and synergistically exploits targeted LNP (lipid nanoparticle) delivery and cell-selective translation of its synthetic mRNA, controlling the amount and site of protein produced, without the need for any genetic editing or the risk of genomic integration. Our proprietary best-in-class decorated lipid nanoparticle technology allows us to achieve in situ cell engineering via systemic, targeted, extra-hepatic delivery to specific tissues and cells, such as T cells. The delivery capability, combined with the translation of cell-selective mRNA, eliminates off-target effects. This expertise is enabled by Kernal Bio’s proprietary machine learning (ML) powered platform that discovers RNA sequence motifs from clinical human data with preferential translation based on cell type.
SOURCE Kernal Biologics